Adaptimmune completes $104 million round of financing to advance cancer therapies
Adaptimmune, a UK biotech company focused on using T-cell therapy to treat cancer and infectious disease, has completed a $104 million Series A financing round, and plans to use the proceeds to advance the company’s internal programs into the clinic in multiple cancer indications.
In June the company entered into a strategic collaboration and licensing agreement with UK pharma major GlaxoSmithKline (LSE: GSK) covering an option on the NY-ESO-1 clinical program, a cancer testis antigen.
The financing round was led by New Enterprise Associates, and additional new investors participating included OrbiMed Advisors, Wellington Management Company, Fidelity Biosciences, Foresite Capital Management and Novo A/S. The University of Oxford was among existing investors participating.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze